---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-24-000015"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:26:10.057916+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# iBio raises ~$15.1M in PIPE at $2.85/unit (148% premium), extends cash runway through FY2025

## Summary
- Gross proceeds of ~$15.1M from common shares, pre-funded warrants, and Series E warrants at $2.85 per unit.
- Net proceeds of ~$14.1M; intended for R&D and working capital, extending cash runway through fiscal 2025.
- Series E warrants exercisable after 6 months at $2.64/share for 5 years; $2.85 price represents 148% premium to last close.
- Amended credit agreement with Woodforest National Bank, extending term loan maturity to May 15, 2024.
- Q3 FY2024 saw exercise of 1,131,500 Class C and 1,006,500 Class D warrants; shares outstanding now 8,515,226.

## SEC filing metadata
- accession: 0001420720-24-000015
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000015/0001420720-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000015/ibio-20240326x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-24-000015
- JSON: https://secwatch.observer/filing/0001420720-24-000015.json
- Plain text: https://secwatch.observer/filing/0001420720-24-000015.txt

## Key facts
- Material Agreements
  iBio, Inc. entered into Purchase Agreement with several institutional investors and an accredited investor valued at gross proceeds of approximately $15.1 million (effective 2024-03-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: several institutional investors and an accredited investor
  - Value: gross proceeds of approximately $15.1 million
  - Effective: 2024-03-26
  source text: On March 26, 2024, iBio, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with several institutional investors and an accredited investor (the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of the following securities for gross proceeds of approximately $15.1 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000015/0001420720-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.